RxDoctor Payments Data

Jaekyoung Hong, MD

Interventional Cardiology · Medford, ORNPI 1093827883

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,577 of the $1,933 with a category attached, or 81.6%. 7 manufacturers reported payments, led by Abbott at 41.3% of the total. 2025 is the largest year on record at $1,051, 6.6 times the $158 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in OR, where the typical reported total is $4,729.

$1,933in general payments, 2019–2025

Across 46 payments — averaging $42.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$799
  • Edwards Lifesciences$517
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
  • Medtronic$127
  • Boston Scientific$99
  • Cardiovascular Systems Inc.$95
  • plus $31 from 1 others

What the payments were for

  • Travel & lodging$35618%
  • Food & beverage$1,57782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,933 in reported general payments places this provider in the 30th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$184,818
Medicare patients
741
Services billed
2,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$254,816
XareltoRivaroxaban104$130,225
Repatha SureclickEvolocumab20$30,604
EntrestoSacubitril/Valsartan22$24,221
JardianceEmpagliflozin19$21,027
Praluent PenAlirocumab13$11,066
BrilintaTicagrelor22$10,929
Repatha SyringeEvolocumab13$10,531
Flecainide Acetate123$6,576
Dofetilide11$6,523
Metoprolol Succinate345$6,006
Rosuvastatin Calcium251$2,927
Losartan Potassium296$2,877
Atorvastatin Calcium173$2,761
Potassium Chloride112$2,234

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →